AstraZeneca Discloses Director’s Gift of Shares to Spouse

An update from AstraZeneca ( (GB:AZN) ) is now available.

AstraZeneca has disclosed an internal share transfer involving Non-Executive Director and PDMR Philip Broadley, who gifted 5,735 ordinary shares in the company to his spouse, Gillian Broadley, for no consideration on 17 December 2025. The off-market transaction, notified in line with UK Market Abuse Regulation requirements, represents a reallocation of shares within a closely associated person group rather than a change in overall insider ownership, and is primarily relevant for transparency and compliance purposes rather than signalling any shift in the company’s strategic or financial outlook.

The most recent analyst rating on (GB:AZN) stock is a Sell with a £105.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Spark’s Take on GB:AZN Stock

According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.

AstraZeneca’s strong financial performance and positive earnings call are the most significant factors driving the score. The company’s strategic expansions and product approvals further enhance its outlook. However, the high valuation and moderate technical indicators slightly temper the overall score.

To see Spark’s full report on GB:AZN stock, click here.

More about AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, UK, specialising in the discovery, development and commercialisation of prescription medicines in oncology, rare diseases and broader biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology, with products sold in more than 125 countries.

Average Trading Volume: 2,109,756

Technical Sentiment Signal: Buy

Current Market Cap: £210.1B

Find detailed analytics on AZN stock on TipRanks’ Stock Analysis page.